Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID‑19 patients: A single centre non‑randomized controlled trial

Novacescu,Alexandru Noris; Duma,Georgiana; Buzzi,Bettina; Baditoiu,Luminita Mirela; Bedreag,Ovidiu; Papurica,Marius; Sandesc,Dorel; Sorescu,Teodora; Vlad,Daliborca; Licker,Monica

doi:10.3892/etm.2021.10999

Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID‑19 patients: A single centre non‑randomized controlled trial

Authors:
- Alexandru Noris Novacescu
- Georgiana Duma
- Bettina Buzzi
- Luminita Mirela Baditoiu
- Ovidiu Bedreag
- Marius Papurica
- Dorel Sandesc
- Teodora Sorescu
- Daliborca Vlad
- Monica Licker
View Affiliations

Affiliations: Doctoral School, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Intensive Care Unit, ‘Dr Teodor Andrei’ Municipal Hospital, 305500 Lugoj, Romania, Intensive Care Unit, ‘Pius Brînzeu’ Emergency Clinical County Hospital, 300723 Timisoara, Romania, Department of Epidemiology, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Diabetes, Nutrition and Metabolic Diseases, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Pharmacology, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Multidisciplinary Research Centre on Antimicrobial Resistance, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania
Published online on: November 24, 2021 https://doi.org/10.3892/etm.2021.10999
Article Number: 76
Copyright: © Novacescu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID‑19 patients. The aim of the present study was to determine whether combining TPE with convalescent plasma (CVP) transfusion early in the intensive care unit (ICU) stay improves survival among this heterogeneous population. The primary endpoint was survival at 30 days. Secondary endpoints included assessing the evolution of biomarkers, such as the partial pressure of arterial oxygen to fractional inspired oxygen ratio, and C reactive protein (CRP), lactate dehydrogenase (LDH) and ferritin levels at the 7‑day follow‑up. This single centre, prospective, non‑randomized controlled trial was conducted in an 8‑bed COVID‑19 ICU and included patients with severe COVID‑19 pneumonia requiring intensive care treatment. A total of 19 patients were treated by performing TPE followed by CVP transfusion, in addition to standard treatment, while for another 19 patients, only standard treatment according to hospital protocols was used. TPE was initiated during the first 24 h after ICU admission, followed immediately by transfusion of CVP. Survival at 30 days was 47.37% in the TPE CVP group and 26.32% in the control group (P=0.002). Patients in the TPE CVP group also showed better oxygenation and a reduction in inflammation, with decreased CRP, LDH and ferritin levels compared with those in the control group. Overall, the study indicated that early initiation of TPE followed by CVP transfusion may be a valid rescue therapy in severe and critically ill COVID‑19 patients, with a statistically significant survival benefit, improved oxygenation and a reduction in inflammatory markers. The trial was registered in the ClinicalTrials.gov database (trial registration number: NCT04973488) on July 22, 2021 (retrospectively registered).

View Figures

View References

1	Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 46:3–16. 2020.PubMed/NCBI View Article : Google Scholar
2	Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ and Prescott HC: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 324:782–793. 2020.PubMed/NCBI View Article : Google Scholar
3	Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar
4	Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med. 45:1631–1643. 2020.PubMed/NCBI View Article : Google Scholar
5	Siddiqi HK and Mehra MR: COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Hear Lung Transplant. 39:405–407. 2020.PubMed/NCBI View Article : Google Scholar
6	Lin L and Li TS: Interpretation of ‘guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the national health commission (trial version 5)’. Zhonghua Yi Xue Za Zhi. 100:805–807. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese), (Online ahead of print).
7	COVID-19 Treatment Guidelines Panel: Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed June 15, 2021.
8	ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L and Slutsky AS: Acute respiratory distress syndrome: The Berlin definition. JAMA. 307:2526–2533. 2012.PubMed/NCBI View Article : Google Scholar
9	Martínez Chamorro E, Díez Tascón A, Ibáñez Sanz L, Ossaba Vélez S and Borruel Nacenta S: Radiologic diagnosis of patients with COVID-19. Radiologia (Engl Ed). 63:56–73. 2021.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).
10	Knaus WA, Draper EA, Wagner DP and Zimmerman JE: Apache II. A severity of disease classification system. Crit Care Med. 13:818–829. 1985.PubMed/NCBI
11	Franchini M and Liumbruno GM: Convalescent plasma for the treatment of severe COVID-19. Biologics. 15:31–38. 2021.PubMed/NCBI View Article : Google Scholar
12	Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, et al: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 324:460–470. 2020.PubMed/NCBI View Article : Google Scholar
13	Keith P, Day M, Perkins L, Moyer L, Hewitt K and Wells A: A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 24(128)2020.PubMed/NCBI View Article : Google Scholar
14	Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M, Pandak N, Al Khalili H and Memish Z: Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 99:214–218. 2020.PubMed/NCBI View Article : Google Scholar
15	Gucyetmez B, Atalan HK, Sertdemir I, Cakir U and Telci L: COVID-19 Study Group. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: A retrospective study. Crit Care. 24(492)2020.PubMed/NCBI View Article : Google Scholar
16	Sarfraz A, Makkar SS, Sarfraz Z, Hathaway III D, Paul T, Sana MK, Talalaev M, Perez-Fernandez J and Yatzkan G: Therapeutic plasma exchange and COVID-19: A rapid review. J Clin Immunol Immunother. 6(041)2020.
17	Balagholi S, Dabbaghi R, Eshghi P, Mousavi SA, Heshmati F and Mohammadi S: Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy. Transfus Apher Sci. 59(102993)2020.PubMed/NCBI View Article : Google Scholar
18	Kamran SM, Mirza ZE, Naseem A, Liaqat J, Fazal I, Alamgir W, Saeed F, Saleem S, Nisar S, Yousaf MA, et al: Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study. PLoS One. 16(e0244853)2021.PubMed/NCBI View Article : Google Scholar
19	Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, et al: Convalescent plasma treatment of severe COVID-19: A matched control study. Nat Med. 26:1708–1713. 2020.PubMed/NCBI View Article : Google Scholar
20	Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, Li J, Wang Z, Wu W, Wu M, et al: Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 136:755–759. 2020.PubMed/NCBI View Article : Google Scholar
21	Jaiswal V, Nasa P, Raouf M, Gupta M, Dewedar H, Mohammad H, Al Rais Z, Ali Baqer M, Alsabbah A, Ibrahim Y, et al: Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-an exploratory study. Int J Infect Dis. 102:332–334. 2021.PubMed/NCBI View Article : Google Scholar
22	Stahl K, Bode C and David S: First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit Care. 24(363)2020.PubMed/NCBI View Article : Google Scholar
23	Honore PM, Barreto Gutierrez L, Kugener L, Redant S, Attou R, Gallerani A and De Bels D: Plasma exchange in critically ill COVID-19 patients improved inflammation, microcirculatory clot formation, and hypotension, thereby improving clinical outcomes: Fact or fiction? Crit Care. 24(551)2020.PubMed/NCBI View Article : Google Scholar
24	Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A and Menichetti F: Patient-blood management for COVID19 convalescent plasma therapy: Relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 27:987–992. 2021.PubMed/NCBI View Article : Google Scholar
25	Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, et al: Diverse functional autoantibodies in patients with COVID-19. Nature. 595:283–288. 2021.PubMed/NCBI View Article : Google Scholar
26	Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, et al: SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 11(5493)2020.PubMed/NCBI View Article : Google Scholar
27	Vuitton DA, Vuitton L, Seillès E and Galanaud P: A plea for the pathogenic role of immune complexes in severe Covid-19. Clin Immunol. 217(108493)2020.PubMed/NCBI View Article : Google Scholar